Peripheral Intravenous Catheters Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Peripheral Intravenous Catheters Market Trends and Insights

Rising Burden of Chronic and Acute Diseases

Diabetes-related disability-adjusted life years climbed more than 80% since 2000, amplifying demand for dependable vascular access across acute and long-term care settings. Aging populations in the United States, Japan, and Western Europe are experiencing multi-morbidities that necessitate longer dwell catheters and higher infusion frequencies. Hospitals are validating polyurethane materials showing 52.9 MPa tensile strength yet 90% light transmittance, which improves site visualization and reduces unplanned restarts. Personalized oncology and biologic regimens demand consistent flow rates over extended durations, leading providers to favor midline and extended-dwell devices that decrease insertion trauma. Collectively, these epidemiological dynamics sustain steady volume growth and reward suppliers that bring infection-resistant, high-clarity catheters to market.

Expansion of Outpatient and Home Infusion Settings

ASCs are forecast to process 44 million procedures by 2034, a 21% jump from 2024, reshaping where vascular access is initiated. Outpatient migration accelerates purchasing of devices designed for maintenance outside the ICU, including integrated extension tubing that keeps systems closed during therapy. Home infusion protocols now emphasize devices that hold patency with minimal nurse intervention, as outlined in the 2024 Infusion Therapy Standards of Practice. Digital ultrasound systems such as BD’s SiteRite 9 pair imaging with needle tracking, increasing first-attempt success rates and reducing unscheduled hospital visits. These care-delivery shifts favor suppliers that bundle catheters with portable guidance tools, consumables, and education modules for non-hospital staff.

Regulatory Mandates on Needlestick and Blood-Exposure Safety

The FDA classified force-activated separation devices as Class II under special controls in 2024, driving procurement toward safety-engineered catheters^{[1]Federal Register, “Intravenous Catheter Classification,” FEDERALREGISTER.GOV}. U.S. health systems face liability risks averaging USD 890 per needlestick episode, strengthening ROI arguments for blood-control hubs. Ultrasound guidance increases pediatric first-attempt success rates to 85.4% compared with 45.8% using palpation, lowering insertion-related injury events. Group purchasing organizations have aligned contract terms with these mandates, giving safety designs priority tiers in value-analysis committees. As regulators expand oversight, conventional open-hub products risk gradual phase-out, accelerating share shifts toward closed, automated safety systems.

Continuous Product Innovation in Catheter Materials and Design

Silicone-based adhesive platforms reduce visible skin damage versus acrylic fixtures, supporting patient comfort in outpatient and pediatrics. Radiopaque polyurethanes optimize in-procedure visibility without sacrificing flexibility, bolstering adoption in interventional imaging suites. Embedded sensor arrays enable real-time pressure and flow monitoring, while BD’s Cue needle-tracking algorithm improves placement accuracy during power injections up to 325 psi. Such multifunctional designs command premiums but demonstrate downstream cost offsets through fewer restarts and complications. Consequently, R&D pipelines target antimicrobial coatings, biodegradable shafts, and smart hubs that integrate with electronic medical records to document dwell times automatically.

High Incidence of Catheter Failures and Complications

First-pass cannulation fails in 40% of attempts, spiking to 70% in difficult-access cohorts, adding an estimated USD 2.68 billion in emergency department costs each year in the United States. Device recalls, such as the FDA’s early alert on specific PowerPICC lots, erode clinician confidence and trigger unbudgeted replacement cycles. Central line-associated bloodstream infections still account for roughly 20% of healthcare-associated bacteremia, prompting exploration of hubs that generate on-site hypochlorous acid for continuous disinfection. Mitigating these failures requires more training, ultrasound capital, and robust data tracking, costs that smaller hospitals may struggle to absorb in the short term.

Environmental Sustainability and Waste-Disposal Concerns

Single-use catheter programs in the United States generate 206 million liters of waste annually, provoking calls for greener alternatives. The NHS is piloting centralized waste-reduction frameworks that reward suppliers offering recyclable or reusable sets^{[2]Brighton and Sussex Medical School, “Sustainable Medical Devices Report,” BSMS.AC.UK}. Biodegradable polymers—polyhydroxyalkanoates, polylactic acid, polybutylene succinate—remain under investigation but must match clinical performance at competitive cost. U.S. policy makers are integrating life-cycle assessments into device approvals, requiring manufacturers to document carbon reductions across supply chains. Although sustainability boosts brand value, re-processing workflows and sterilization infrastructure create near-term complexity that may dampen adoption pace.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Midlines Strengthen Extended-Dwell Adoption

Midline catheters generated the fastest 8.21% CAGR through 2031, even as short IV catheters retained 60.58% revenue in 2025, a position underscored by their versatility in routine infusions. Clinical trials have verified that midlines cut bloodstream infection risk relative to peripherally inserted central catheters for intermediate-duration therapies. The peripheral intravenous catheters market size for midlines is forecast to widen further as chronic-care pathways migrate to outpatient venues.

Design updates center on soft-tip radiopaque shafts, integrated stabilizers, and closed connectors that remain occlusion-free longer than 28 days. Regulatory clearance for B. Braun’s Introcan Safety 2 Deep Access IV Catheter illustrates how automatic needle shielding and enhanced flow rates are converging to reinforce clinician confidence. While price-sensitive buyers still rely on basic short catheters, the clinical imperative to minimize reinsertion events positions midlines as a rising standard for oncology, heart-failure, and complex antibiotic regimens.

By Technology: Safety Systems Move From Premium to Mainstream

Safety and blood-control formats held 67.95% of 2025 revenue and are adding 8.54% CAGR, signaling that compliance is outpacing cost as the pivotal procurement criterion. Closed-hub valves and automatic retraction needles are now embedded across flagship portfolios such as BD Insyte Autoguard BC, which cuts blood exposure by 95%. The peripheral intravenous catheters market continues to phase out conventional open-hub products, especially in high-litigation regions.

Professional societies recommend pairing safety catheters with bedside ultrasound; 2024 guidelines from the American Society of Echocardiography endorse factory-integrated flashback chambers and blunt cannulae to cut insertion trauma. As hospitals track sharps-injury metrics on public dashboards, risk-adjusted reimbursement models are beginning to penalize facilities with high incident rates, reinforcing the switch to safety devices.

By Material: Silicone Gains Ground on Comfort Metrics

Polyurethane still accounts for 57.02% of revenue owing to its tensile strength and chemical compatibility, but silicone is charting the highest 8.33% CAGR as outpatient dwell times lengthen. The peripheral intravenous catheters market share leadership of polyurethane stems from broad SKU availability and price competitiveness; however, silicone’s softer modulus lowers phlebitis incidence, a value recognized in pediatric oncology protocols.

Manufacturers are experimenting with polyurethane-urea blends that retain 90% transparency at 550 nm while boosting durability, bridging the performance gap and allowing visualization during insertion. Future materials roadmaps focus on antimicrobial additives, hydrophilic interiors to reduce thrombosis, and recycled content that aligns with ESG procurement criteria.

By End User: ASC Growth Redefines Channel Mix

Hospitals captured 71.62% of 2025 revenues, reflecting their central role in trauma, critical care, and high-acuity procedures. Yet ASCs, advancing at 9.35% CAGR, are redefining channel priorities as payers encourage same-day discharge pathways. Medicare spent USD 6.1 billion on ASC services for 3.3 million beneficiaries in 2022, underscoring the volume at stake.

The peripheral intravenous catheters market now sees manufacturers fielding compact insertion kits with color-coded components specifically for outpatient turnover. Home health agencies and infusion pharmacies represent adjacent expansion zones, each requiring remote training portals and tamper-evident packaging to assure adherence and safety.

By Application: Diagnostics Propel High-Pressure Designs

Medication administration remained the largest use case with 44.15% of 2025 sales, while diagnostic imaging and contrast delivery is scaling at a 9.22% CAGR amid expanding CT and MRI capacity. BD’s Nexiva Diffusics employs a laser-cut diffusion tip that tolerates power-injection up to 325 psi without compromising vessel integrity. This capability broadens peripheral access into radiology suites, mitigating the need for central lines and reducing overall procedure time.

The peripheral intravenous catheters market size for diagnostic applications is set to increase as interventional radiologists rely on multi-phase contrast studies requiring rapid, high-flow bolus delivery. Fluid resuscitation and nutrition infusions remain core but mature, whereas transfusion-specific devices command niche volumes tied to hemovigilance protocols.

Geography Analysis

North America generated 39.88% of 2025 revenue, anchored by the United States, where annual consumption exceeds 300 million units. Robust reimbursement and hospital investment in safety portfolios sustain premium average selling prices. The region is adding ultrasound-guided insertion modules, remote vascular-access credentialing, and predictive analytics dashboards that monitor catheter dwell time compliance. Canada and Mexico broaden regional scale through public-sector tenders and new maquiladora manufacturing footprints, respectively.

Europe, a mature regulatory environment, balances patient-safety mandates with emergent circular-economy requirements. Germany, France, and the United Kingdom account for the majority of regional demand, while Spain and Italy adopt reuse pilots to curb single-use plastics. EU Medical Device Regulation enforcement compels suppliers to refresh technical documentation and post-market surveillance, elevating market-entry barriers for new entrants. Public procurement frameworks now weight sustainability alongside clinical evidence, fostering dialogue on recycled polymers and extended-life formats.

Asia-Pacific is the fastest-growing geography at 7.34% CAGR, driven by China, India, Japan, South Korea, and Australia. India’s medical technology sector is set to scale from USD 16–17 billion to USD 50 billion by 2030 under the New Drugs, Medical Devices and Cosmetics Bill of 2023, catalyzing domestic manufacturing alliances. China leverages cost-effective mass production yet is investing in premium image-guided systems to serve tertiary hospitals. Japan’s super-aged society necessitates advanced silicone designs for fragile veins, while Australia focuses on infection-prevention benchmarks that align with national quality indicators. Collectively, these trends expand the peripheral intravenous catheters market footprint across price tiers, compelling multinationals to localize supply chains and co-develop clinical education platforms.

Regulatory Landscape

In the United States, the FDA action in August 2024 reclassified intravenous catheter force-activated separation devices as Class II under special controls. This has reinforced procurement movement toward safety features intended to mitigate needlestick and blood exposure in hospital risk programs.

In Europe, EU MDR implementation has tightened documentation and registration requirements while creating relief paths for established technologies. In March 2026, the European Commission adopted delegated regulations expanding the Well-Established Technologies list to include peripheral catheters and cannulas under EU MDR 2017/745, with mandatory EUDAMED registration for new MDR/IVDR devices starting May 28, 2026. A parallel MDCG guidance refresh in April 2026, along with ongoing ISO 10555-5 revision influence, is expected to shape verification and submission planning.

Market Opportunities and Future Outlook

Opportunities around prevention of bloodstream infections, reduction of blood exposure, and preservation of peripheral veins are pushing providers toward closed systems and imaging-guided insertion workflows. The May 2024 WHO guideline on preventing bloodstream infections associated with peripheral catheters offers a commonly referenced baseline for insertion, maintenance, and timely removal, which supports bundled device and protocol offerings across hospitals, ambulatory surgical centers, and alternate care sites.

In Europe, regulatory modernization and in North America safety-driven tendering are both shaping procurement toward premium safety and closed designs. The EU MDR shift, including mandatory EUDAMED registration starting May 28, 2026 and the 2026 Well-Established Technologies expansion to peripheral catheters and cannulas, raises the bar for technical files and post-market surveillance readiness, and it narrows the window for new entries that do not align on classification and evidence. In parallel, growth in outpatient and home infusion care is extending demand for extended-dwell peripheral options and imaging-guided insertion workflows that are already visible in leading product portfolios.